Stock Quote (NASDAQ: NSTG)
Price:
19.36
Change:
+ 0.20
Day High:
19.51
Day Low:
19.10
Volume:
83,717
4:00 PM ET on Mar 24, 2017
Delayed at least 20 minutes.
Provided by eSignal.


Search Investor Relations

Press Releases

All Releases
View Summary PRESS RELEASEMar 23, 2017
NanoString Launches New PlexSet Technology as an Alternative to qPCR for Multiplexed High-Throughput Gene Expression Studies
read more
View Summary PRESS RELEASEMar 01, 2017
NanoString Technologies Releases Fourth Quarter and Full Year 2016 Operating Results and Provides 2017 Outlook
read more
View Summary PRESS RELEASEFeb 27, 2017
The Novartis Institutes for BioMedical Research and NanoString Technologies Demonstrate a Novel Approach for High-Plex, Spatial Profiling of Proteins Using nCounter-Based Digital Quantification at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium
read more
View Summary PRESS RELEASEFeb 24, 2017
NanoString Technologies to Release Fourth Quarter and Fiscal Year 2016 Financial Results and Host Conference Call on Wednesday, March 1, 2017
read more
View Summary PRESS RELEASEFeb 22, 2017
NanoString Technologies to Present at the Cowen and Company 37th Annual Health Care Conference
read more
View Summary PRESS RELEASEFeb 16, 2017
NanoString Highlights Progress on Product Roadmap Featuring Multiple Innovative Technologies at 2017 Advances in Genome Biology and Technology (AGBT) Conference
read more
View Summary PRESS RELEASEJan 31, 2017
Humana Issues Positive Coverage Decision for NanoString's Prosigna® Breast Cancer Assay
read more
View Summary PRESS RELEASEJan 10, 2017
Blue Cross Blue Shield Association Evidence Street Issues Positive Assessment for NanoString's Prosigna® Breast Cancer Assay
read more
View Summary PRESS RELEASEJan 10, 2017
NanoString Technologies Provides Preliminary Operational and Financial Results for 2016
read more
View Summary PRESS RELEASEDec 22, 2016
NanoString Technologies to Present at J.P. Morgan 35th Annual Healthcare Conference
read more
View Summary PRESS RELEASEDec 12, 2016
Prosigna Breast Cancer Assay Outperforms All Other Commercial Assays Tested in Updated Analysis of TransATAC Study Presented at the 39th Annual CTRC-AACR San Antonio Breast Cancer Symposium
read more
View Summary PRESS RELEASEDec 05, 2016
NanoString Technologies Highlights Presentation of Multiple Prosigna/PAM50 and Immuno-Oncology Studies at the 39th Annual CTRC-AACR San Antonio Breast Cancer Symposium
read more
View Summary PRESS RELEASEDec 01, 2016
The Scientist Magazine Names NanoString Technologies nCounter Vantage 3D Panels a Top 10 Innovation of 2016
read more
View Summary PRESS RELEASENov 30, 2016
NanoString Technologies Highlights Advances in Precision Oncology at the 58th Annual Meeting of the American Society of Hematology
read more
View Summary PRESS RELEASENov 11, 2016
NanoString Technologies Teams with the OHSU Knight Cancer Institute to Develop Myeloid Gene Expression Panels to Advance Immuno-Oncology Research
read more
View Summary PRESS RELEASENov 07, 2016
NanoString Launches Technology Access Program (TAP) for Transformative Platform for High-Plex Digital Spatial Profiling
read more
View Summary PRESS RELEASENov 02, 2016
NanoString Technologies Releases Operating Results for Third Quarter of 2016
read more
View Summary PRESS RELEASEOct 19, 2016
NanoString Technologies Presents Update on Hyb & Seq™ Next-Generation Sequencing Chemistry at ASHG Annual Meeting
read more
View Summary PRESS RELEASEOct 18, 2016
NanoString Enhances Solid Tumor Profiling with 3D Biology Capabilities for Formalin-Fixed, Paraffin-Embedded (FFPE) Tissue Samples
read more
View Summary PRESS RELEASEOct 05, 2016
NanoString Technologies to Release Third Quarter 2016 Financial Results and Host Conference Call on Wednesday, November 2, 2016
read more
Showing 1-20 of 183 Page: 1 2 3 4 5 ... 10  Next 20